CA2199945C - X-ray emitting interstitial implants - Google Patents
X-ray emitting interstitial implants Download PDFInfo
- Publication number
- CA2199945C CA2199945C CA002199945A CA2199945A CA2199945C CA 2199945 C CA2199945 C CA 2199945C CA 002199945 A CA002199945 A CA 002199945A CA 2199945 A CA2199945 A CA 2199945A CA 2199945 C CA2199945 C CA 2199945C
- Authority
- CA
- Canada
- Prior art keywords
- seed
- palladium
- ray emitting
- carrier
- support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000007943 implant Substances 0.000 title description 7
- KDLHZDBZIXYQEI-OIOBTWANSA-N palladium-103 Chemical compound [103Pd] KDLHZDBZIXYQEI-OIOBTWANSA-N 0.000 claims abstract description 121
- 230000000694 effects Effects 0.000 claims abstract description 46
- 239000008188 pellet Substances 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 24
- 238000009713 electroplating Methods 0.000 claims abstract description 14
- 239000002245 particle Substances 0.000 claims abstract description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 109
- 229910052763 palladium Inorganic materials 0.000 claims description 41
- 239000010948 rhodium Substances 0.000 claims description 36
- 229910052751 metal Inorganic materials 0.000 claims description 32
- 239000002184 metal Substances 0.000 claims description 32
- 230000005855 radiation Effects 0.000 claims description 23
- 229910052703 rhodium Inorganic materials 0.000 claims description 21
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 8
- 238000002513 implantation Methods 0.000 claims description 7
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 6
- 238000009826 distribution Methods 0.000 claims description 6
- 239000010936 titanium Substances 0.000 claims description 6
- 229910052719 titanium Inorganic materials 0.000 claims description 6
- 239000000560 biocompatible material Substances 0.000 claims description 5
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 239000011257 shell material Substances 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000002285 radioactive effect Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 230000000155 isotopic effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 230000004907 flux Effects 0.000 description 5
- 229910002804 graphite Inorganic materials 0.000 description 5
- 239000010439 graphite Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 150000003283 rhodium Chemical class 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 231100000987 absorbed dose Toxicity 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical group [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 3
- 229940044173 iodine-125 Drugs 0.000 description 3
- -1 palladium amine Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229910017974 NH40H Inorganic materials 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- PCHJSUWPFVWCPO-OUBTZVSYSA-N gold-198 Chemical compound [198Au] PCHJSUWPFVWCPO-OUBTZVSYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- 241000518994 Conta Species 0.000 description 1
- 241001536352 Fraxinus americana Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002914 transuranic radioactive waste Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1027—Interstitial radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N2005/1019—Sources therefor
- A61N2005/1024—Seeds
Abstract
Safe, isotopically pure Pd-103-containing seeds (10) of high apparent activity are formed by bombarding an Rh target in a cyclotron with high energy particles to obtain Rh containing carrier-free Pd-103, separating therefrom the carrier-free Pd-103, adding a small amount of Pd to the carrier-free Pd-103, electroplating said Pd-103/Pd admixture to a pellet(s) (14) of electroconductive material and encapsulating the pellet(s) (14) within a bi-compatible container or shell (22).
Description
WO 96!15830 ~ ~ ~ ~ pCTlUS94/13486 X-RAY EI~iITTING INTERSTITIAL IMPLANTS
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to therapeutic radiation oncology. 3~tore particularly, the present invention is directed to a radioactive X-ray source commonly referred to as a seed for interstitial implantation and to its method of manufacture.
DESCRIPTION OF THE PRIOR ART
Interstitial implantation of radiation-emitting materials for localized tumor treatment has lona been recognized. The advantages of interstitial implants reside in their ability to concentrate the radiation on the tumor tissue while minimizing radiation exposure to normal tissue. Commonly used implantable materials include radioactive gold (gold-198) and radon-222. These materials are not without their shortcomings, however, since the highly penetrating radiation they emit not only subject normal tissue to more destructive radiation, but also make it difficult to adequately shield the administering personnel from the radiation emitted.
Another isotope commonly used for seed manufacture is iodine-125. The general effectiveness of these seeds has been,described in several publications such as ~~The Use of Iodine-125 for Interstitial Implants, U.S. Department of Health, Education and Welfare Publication (FDA) 76-8022, Basil Hilaris et al, November 1975 and in U.S. Patent No. 3,351,049.
U.S. Patent No. 3,351,049 to Lawrence et al suggests the use of carrier-free palladium 103 as therapeutic seeds. Carrier-free palladium 103 (i.e., palladium 103 which does not contain palladium metal or other palladium isotopes) has never been incorporated in commercially-available
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to therapeutic radiation oncology. 3~tore particularly, the present invention is directed to a radioactive X-ray source commonly referred to as a seed for interstitial implantation and to its method of manufacture.
DESCRIPTION OF THE PRIOR ART
Interstitial implantation of radiation-emitting materials for localized tumor treatment has lona been recognized. The advantages of interstitial implants reside in their ability to concentrate the radiation on the tumor tissue while minimizing radiation exposure to normal tissue. Commonly used implantable materials include radioactive gold (gold-198) and radon-222. These materials are not without their shortcomings, however, since the highly penetrating radiation they emit not only subject normal tissue to more destructive radiation, but also make it difficult to adequately shield the administering personnel from the radiation emitted.
Another isotope commonly used for seed manufacture is iodine-125. The general effectiveness of these seeds has been,described in several publications such as ~~The Use of Iodine-125 for Interstitial Implants, U.S. Department of Health, Education and Welfare Publication (FDA) 76-8022, Basil Hilaris et al, November 1975 and in U.S. Patent No. 3,351,049.
U.S. Patent No. 3,351,049 to Lawrence et al suggests the use of carrier-free palladium 103 as therapeutic seeds. Carrier-free palladium 103 (i.e., palladium 103 which does not contain palladium metal or other palladium isotopes) has never been incorporated in commercially-available
- 2 -tumor-treating materials because its short 17-day half-life makes it difficult to work with in view of the processing time required to isolate and purify the isotope. Perhaps of greater concern is the difficulty in producing a carrier-free palladium 103 seed 'which is safe in case of a failure of the seed outer conta.i:ner, that is, a seed from which the palladium 103 cannot escape from its supporting medium inside the seed and migrate into the blood stream and/or normal tissue of patients treated in the event of such a failure. Numerous articles describe preparation of carrier-free palladium, from cyclotrons as, for example, W.M.
Garrison, J.G. Hamilton., U.S. Atomic Energy Commission, UCRL-1067 (1950); P.V. Harper, K.A. Lathrop and J.L. Need, "The Thick Target YieldL and Extraction Function for the Reaction Rhlos (p~ n) pdlo3~~ ~ Argonne Cancer Research Hospital Semiannual Report to the Atomic Energy Commission, 15:124 (1961); V.I. Levin et a.l, Separation of pdlos without a Carrier, Otkrytiya, Izobret, 1969, 46(1), 170; V.I. Levin et al, Preparation of Carrier Free Palladium-103 and a Radioactive Colloidal F~alladium Composition for Medicinal Purposes, Radiokhimiya, 13(4), 622-7 (1971); P. Tarapcik and V. Mikulaj, Separation of Palladium 103 from Cyclotron Irradiated Targets, Radiochem. Radioanal. Lett., 48 (1981) 1969, 46. In all instances, however, only small amount of the isotope have been prepared, and then only for research purposes.
U.S. Patent No. 4,702,228 does describe therapeutic seeds containing palladium 103 prepared by increasing the Pd-102 content found in palladium metal, i.e., by enriching palladium metal in 'WO 96/15830 ~ ~ ~ ~ g ~ ~ PCT/US94/13486
Garrison, J.G. Hamilton., U.S. Atomic Energy Commission, UCRL-1067 (1950); P.V. Harper, K.A. Lathrop and J.L. Need, "The Thick Target YieldL and Extraction Function for the Reaction Rhlos (p~ n) pdlo3~~ ~ Argonne Cancer Research Hospital Semiannual Report to the Atomic Energy Commission, 15:124 (1961); V.I. Levin et a.l, Separation of pdlos without a Carrier, Otkrytiya, Izobret, 1969, 46(1), 170; V.I. Levin et al, Preparation of Carrier Free Palladium-103 and a Radioactive Colloidal F~alladium Composition for Medicinal Purposes, Radiokhimiya, 13(4), 622-7 (1971); P. Tarapcik and V. Mikulaj, Separation of Palladium 103 from Cyclotron Irradiated Targets, Radiochem. Radioanal. Lett., 48 (1981) 1969, 46. In all instances, however, only small amount of the isotope have been prepared, and then only for research purposes.
U.S. Patent No. 4,702,228 does describe therapeutic seeds containing palladium 103 prepared by increasing the Pd-102 content found in palladium metal, i.e., by enriching palladium metal in 'WO 96/15830 ~ ~ ~ ~ g ~ ~ PCT/US94/13486
- 3 -palladium 102 and then by exposing it to a neutron , flux so as to convert a small fraction of the . palladium 102 to palladium 103. Seeds prepared in accordance with the process of this patent have been commercially successful, but are not without their shortcomings.
Unlike cyclotron palladium 103 production wherein carrier-free palladium 103 can be produced, nuclear reactor produced-palladium 103 is not carrier-free.
Palladium 103 is produced in a nuclear reactor by bombardir~g a target containing Pd-102 with neutrons (Pd-102(n,y) Pd-103). Since all of the Pd-102 nuclei are not converted and, since in addition, other naturally occurring isotopes of the element palladium are present in the target, Pd-103 cannot be produced in a carrier free state. In addition, since there are always other isotopes of Pd present, neutron activation products of these isotopes are produced as well. For example, the reaction Pd-108(n,y)Pd-109 also occurs and therefore Pd-103 from a reactor is always found in the presence of the radioisotope Pd-109 until the Pd-109 decays out of the matrix. Since Pd-109 is the same element as Pd-103, no chemical means are known to effect their separation. The presence of other nuclides of Pd, also leads to the production of significant activities of certain non-Pd radioisotopes, e.g. Pd-111, which decays to Ag-111, further complicating the radiochemical purification of the Pd-103 matrix. In contrast, carrier-free' Pd-103 produced in a particle accelerator such as a cyclotron enters the purification scheme in a far purer state with essentially no unseparable radioisotopes present.
WO 96/15830 ~ ~ ~ ~ ~ ~ PCT/US94/13486
Unlike cyclotron palladium 103 production wherein carrier-free palladium 103 can be produced, nuclear reactor produced-palladium 103 is not carrier-free.
Palladium 103 is produced in a nuclear reactor by bombardir~g a target containing Pd-102 with neutrons (Pd-102(n,y) Pd-103). Since all of the Pd-102 nuclei are not converted and, since in addition, other naturally occurring isotopes of the element palladium are present in the target, Pd-103 cannot be produced in a carrier free state. In addition, since there are always other isotopes of Pd present, neutron activation products of these isotopes are produced as well. For example, the reaction Pd-108(n,y)Pd-109 also occurs and therefore Pd-103 from a reactor is always found in the presence of the radioisotope Pd-109 until the Pd-109 decays out of the matrix. Since Pd-109 is the same element as Pd-103, no chemical means are known to effect their separation. The presence of other nuclides of Pd, also leads to the production of significant activities of certain non-Pd radioisotopes, e.g. Pd-111, which decays to Ag-111, further complicating the radiochemical purification of the Pd-103 matrix. In contrast, carrier-free' Pd-103 produced in a particle accelerator such as a cyclotron enters the purification scheme in a far purer state with essentially no unseparable radioisotopes present.
WO 96/15830 ~ ~ ~ ~ ~ ~ PCT/US94/13486
- 4 -Another drawback of seeds produced in a nuclear reactor from Pd-102 enriched palladium is that for practical reasons soon to be apparent, one is obliged to use reactor produced Pd-103 at the specific activity level generated in the reactor without adjustment while the specific activity of cyclotron produced Pd-103 can be adjusted to provide for its economical utilization while at the same time providing for the production of a seed of 1o predetermined therapeutic or apparent activity.
The specific activity of Pd-103 that can be produced in a nuclear reactor is determined by the enrichment of the Pd-102 target used, the neutron flux in the reactor and the length of exposure of the target to the neutron flux in the reactor. At this time, the highest enrichment of the Pd-102 available (Oak Ridge National Laboratories (ORNL)) has an isotopic purity of 77.9 Pd-102 with the remaining 22~.1~ made up of the other isotopes of Pd. The highest neutron flux available in the world is found in the ORNL HFIR facility where the level is approximately 2.6E15 neutrons/cm2sec. This reactor runs in 21 day cycles with approximately 3 days between and due to the generation of extraneous isotopes such as Ag-111, the maximum practical irradiation time is two cycles. These factors taken together indicate the maximum specific activity that can be derived from a reactor target is approximately 345 Ci/g.
In contrast, the specific activity of carrier-free Pd-103 is 75,000 Ci/g.
The ability to adjust the specific activity of the Pd-103/palladium mixture onto the support allows the self absorption (the tendency of Pd or other nuclei of high atomic number to adsorb the WO 96/15830 ~ °~ ~ 9 9 4 5 PCTlIlS94/13486 -a low energy X-rays produced when a Pd-103 nucleus disintegrates) to be adjusted to a known value thus . facilitating the manufacture of a seed with an accurately predetermined therapeutic or apparent
The specific activity of Pd-103 that can be produced in a nuclear reactor is determined by the enrichment of the Pd-102 target used, the neutron flux in the reactor and the length of exposure of the target to the neutron flux in the reactor. At this time, the highest enrichment of the Pd-102 available (Oak Ridge National Laboratories (ORNL)) has an isotopic purity of 77.9 Pd-102 with the remaining 22~.1~ made up of the other isotopes of Pd. The highest neutron flux available in the world is found in the ORNL HFIR facility where the level is approximately 2.6E15 neutrons/cm2sec. This reactor runs in 21 day cycles with approximately 3 days between and due to the generation of extraneous isotopes such as Ag-111, the maximum practical irradiation time is two cycles. These factors taken together indicate the maximum specific activity that can be derived from a reactor target is approximately 345 Ci/g.
In contrast, the specific activity of carrier-free Pd-103 is 75,000 Ci/g.
The ability to adjust the specific activity of the Pd-103/palladium mixture onto the support allows the self absorption (the tendency of Pd or other nuclei of high atomic number to adsorb the WO 96/15830 ~ °~ ~ 9 9 4 5 PCTlIlS94/13486 -a low energy X-rays produced when a Pd-103 nucleus disintegrates) to be adjusted to a known value thus . facilitating the manufacture of a seed with an accurately predetermined therapeutic or apparent
5 activity. Such an adjustment procedure is not practical with reactor produced Pd-103 for two reasons: 1) because its specific activity, which is as illustrated above initially much lower than the carrier free~Pd-103 produced in a cyclotron, can only be adjusted downward thereby increasing the amount Pd-103 and, because they are inseparable chemically, the amount of enriched Pd-102 that must be used per seed contrary to the best economic practice of the process and contrary to the conservation of the difficulty replaceable enriched Pd-102 and 2) the addition of palladium metal to reactor produced Pd-102 lowers the enrichment level of the Pd-102 contained in the seeds produced thereby reducing the utility of the Pd-102/palladium mixture recovered from unused seeds, an essential element in the economical utilization of the enriched Pd-102 resource.
gn view of the amounts of contaminating Pd isotopes and non-Pd-isotopes present in Pd-103 produced in a nuclear reactor from Pd-102 enriched Pd and the constantly varying factors involved, e.g. neutron flux, extent of Pd-102 enrichment, exposure time, etc., it is difficult, if not impossible, to predict what the purity and/or specific activity of the resulting Pd-103 product will be for any given production run. Thus, Pd-103 production processes employing Pd-102 enriched Pd do not lend themselves to the design of a process for production of a reproducible product of predetermined activity.
gn view of the amounts of contaminating Pd isotopes and non-Pd-isotopes present in Pd-103 produced in a nuclear reactor from Pd-102 enriched Pd and the constantly varying factors involved, e.g. neutron flux, extent of Pd-102 enrichment, exposure time, etc., it is difficult, if not impossible, to predict what the purity and/or specific activity of the resulting Pd-103 product will be for any given production run. Thus, Pd-103 production processes employing Pd-102 enriched Pd do not lend themselves to the design of a process for production of a reproducible product of predetermined activity.
- 6 -A further shortcoming in seeds produced from Pd-102 enriched Pd resides in the fact that large amounts of Pd-nuclei remain which tend to shield the low energy X-rays released when the Pd-103 nuclei disintegrate. The practical result of this is that additional palladium material containing enriched Pd-102 and Pd-103 must be used to compensate for the X-rays absorbed by the palladium nuclei to attain the desired X-ray intensity outside the interstitial implant device.
Lastly, reactor produced Pd-103 from Pd-102 enriched Pd not only is costly because of the difficulty in enriching Pd metal in Pd-102, but poses environmental problems. Producing Pd-103 with a reactor requires the fission of uranium to produce the required neutrons. An adequate means to dispose of the resulting transuranic waste is still a subject of debate. The larger amounts of contaminant~isotopes produced in a reactor target also present a disposal problem. Since electric power is the only requirement to make a cyclotron function and contaminant isotope production is much less, cyclotron produced Pd-103 has far less of an environmental impact.
It is apparent therefore that if it were possible to produce a seed of Pd-103 of sufficient purity and desired therapeutic activity via the cyclotron route that was also safe, that the advantages it would present over the presently commercially available Pd-103 seeds would be of immeasurable value.
It is an object of the invention,.therefore, to provide a seed of Pd-103 of high isotopic purity and desired therapeutic activity that is also safe for use as an interstitial implant. By the term wo 96n5s3o ~ ~ ~ ~ ~ ~ ~ PCTIUS94/13486 -"safe" as used herein and in appended claims is meant a seed characterized by being non-toxic and having radioisotopically pure Pd-103 bonded to the support carrying same in a manner that preclude .5 release therefrom, thereby substantially reducing the chances of the radioactive isotope leaking into the circulatory system of the patient.
Another object of the invention is to provide an interstitial seed composed of carrier free Pd-103 having added to it small amounts of palladium metal, which seed has an isotopic purity such that the ratio of the radiation absorbed dose to the patient from isotopes other than Pd-103 to that from Pd-103 is less than 0.01 and a specific activity of at least 2.5 Ci/gm.
A further object of the present invention is to provide a process for the production of a safe, Pd-103-containing seed substantially reduced in the self-shielding properties that characterize commercially-available Pd-103 seeds and which therefore enables use of smaller amounts of Pd-103 to achieve the desired X-ray intensity (therapeutic or apparent activity).
Yet another object of the invention is to provide a process for the production of Pd-103 seeds which does not present the purification difficulties encountered in present commercially available Pd-103 production processes.
A further object of the invention is to provide a process for the reproducible production of safe Pd-103 containing seeds of predetermined isotopic purity, self-shielding and therapeutic or apparent activity.
Lastly, the invention provides a process for Pd-103 seed production that is cheaper, does not WO 96/15830 ~ ~ ~ ~ ~ ~ PCT/LTS94/13486 - g -require a difficultly replaced resource (enriched Pd-102) and that poses a reduced threat to the environment.
SUMMARY OF THE INVENTION
These and other objects of the invention are obtained by a process which comprises preparing a seed that is safe for implantation into a tumor within a living body to emit x-ray radiation, said seed having a predetermined radiation level measured as apparent mCi comprising irradiating an Rh metal. target in a charged particle accelerator under conditions that produce carrier-free Pd-103 within said Rh metal, recovering carrier-free Pd-103 from the rhodium metal, adding palladium metal to said carrier-free Pd-103 in a small amount sufficient to promote electroplating of said mixture and to obtain the desired level of self shielding, removing non-palladium isotopes from said admixture, if necessary, electroplating a layer of said Pd-103/palladium admixture having a known specific activity and self absorption onto at least one pellet of an electroconductive material substantially non-absorbing of X-rays, the amount of Pd-103 in said layer being sufficient to provide a radiation level measured as apparent mCi of greater than 0.5, and encapsulating said at least one pellet within a shell of a biocompatible material that is penetrable by X-rays in the 20-23 kev range.
In another aspect of the invention there is obtained a safe seed for implantation into a tumor within a living body to emit x-ray radiation said seed having a predetermined radiation level measured as apparent mCi comprising irradiating a rhodium metal target in a charged particle WO 96!15830 ~ ~ ~ PCT/US94/13486 ~_ accelerator under conditions that produce carrier-free Pd-103 in said rhodium metal, recovering v carrier-free Pd-103 from rhodium metal, adding . palladium metal to said carrier-free Pd-103 in a small amount sufficient to promote electroplating of said mixture and to obtain the desired level of self shielding, removing, if necessary, non-palladium isotopes from said admixture electroplating a layer of said Pd-103/palladium admixture having a known specific activity and self absorption onto at least one pellet of an electroconductive material substantially non-absorbing of X-rays, the amount of Pd-103 in said .
layer being sufficient to provide a radiation level measured as apparent mCi of greater than 0.5, and encapsulating said at least one pellet within a shell of a bicompatible material that is penetrable by X-rays in the 20-23 kev range.
In yet another aspect of the invention, there is provided a seed for safe implantation into tumors which consists of a layer of carrier free Pd-103 having added thereto Pd in an amount that provides a seed having an isotopic purity such~that the ratio of the radiation absorbed dose to the patient from isotopes other than Pd-103 to that from Pd-103 is less than 0.01 and a specific activity of at least 2.5 Ci/gm electroplated onto an electroconductive support, the amount of said Pd being sufficient to promote said electroplating, said at least one electroplated pellet containing Pd-103 in an amount sufficient to provide a radiation level measured as apparent mCi of greater than 0.5, and a shell of a bicompatible material encapsulating said at least one electroplated WO 96/15830 °~~ ~ ~ ~ ~ 4 ~ PCT/LTS94/13486 pellet, said biocompatible material being penetrable by X-rays in the 20-23 kev range.
By the term isotopic purity as used herein and in the appended claims is meant the proportion of the total radiation, absorbed dose due to the specified nuclide, that is, that the dose from other isotopes is less than 1.0% of the Pd-103 dose.
By the term specific activity as used herein and in the appended .claims is meant the total activity of the Pd-103 per gram of the admixture with palladium metal.
By the term "therapeutic or apparent activity" as used herein and the appended claims is meant the Pd-103 activity as determined from measuring the X-ray intensity outside the seed. This is also the therapeutic activity, i.e. the activity that actually kills the cancer and therefore the activity the doctor must use when developing a plan for treating the patient.
$RIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a cut-away view of an implantable X-ray emitting capsule or seed, embodying various features of the present invention; and Fig. 2 is a cut-away view of an alternative embodiment of an implantable seed.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
With reference to the drawings, a seed or capsule 10, embodying features of the invention is 3o implanted at a selected site within a living body and emits localized X-ray radiation therein. The X-rays are emitted from a pair of pellets 14 of generally cylindrical shape of electroconductive material having electroplated thereon the carrier-free Pd-103/Pd admixture of the present invention.
PCTlI7S94113486 wo 96nsg3o Positioned between the two pellets is a rod-shaped marker 18 formed of X-ray-opaque material that provides a means of visualizing the seed 10 with external X-ray equipment after the seed has been implanted in the body.
In accordance with the present invention, a target for use in the charged particle accelerator is prepared by depositing rhodium metal onto a suitable substrate such as a copper or a silver substrate. The rhodium target thus prepared is then placed in a charged particle accelerator such as a cyclotron and bombarded with protons or deuterons. The energy of the impacting particle is chosen so that for all practical purposes the only Pd atoms created on the rhodium target are Pd-103, that is, the Pd-103 is carrier-free. The rhodium metal containing the carrier-free Pd-103 is then placed in a hot cell wherein the rhodium metal is removed from the substrate by, for example, etching away with HN03. This removal is preferably accomplished by mechanically disrupting the continuity of the rhodium layer on the substrate as by perforating the surface with a sharply pointed impact tool. The exposed (i.e. non-deposit-containing) substrate surface is covered to protect it and the perforated target immersed in a HN03 bath. A solution containing rhodium flakes results, which is filtered to recover the solid rhodium flakes containing Pd-103. The recovered rhodium flakes are rinsed on the filter and the flakes together with the filter placed in a crucible and heated to decompose the filter leaving the rhodium metal flakes containing the Pd-103.
The rhodium metal flakes thus obtained are then partially dissolved in molten NaHS04 and the resulting NaHS04/rhodium flake mixture is dissolved in dilute HC1 which provides soluble rhodium salts dissolved in dilute HC1. This procedure is . normally repeated several times so as to dissolve any remaining rhodium metal containing carrier-free palladium-103.
Palladium is then added lusuallv in t-hA
soluble salt such as PdCl2) to the solution containing rhodium salts. Although palladium has a high atomic number and would normally be considered an undesirable additive to a low energy X-ray emitting seed, its addition in accordance with the present invention, has been found to be essential and advantageous in several respects. Foremost, the added palladium promotes the subsequent electroplating and ensures strong adhesive of the Pd-103/Pd mixture to the support therefor, thereby forming a physiologically inert layer which will not allow the radioactive Pd-103 to be mobilized into the circulation of a human should the titanium outer shell be breached and body fluids allowed to come into contact with the Pd-103 containing layer.
Secondly, the addition of palladium metal represents the ability to adjust the specific activity of the Pd-103/palladium mixture electroplated onto the support with the objective of adjusting its self absorption to a known value thus facilitating the manufacture of a seed with an accurately predetermined therapeutic or apparent activity. Thirdly, if further purification of the carrier-free Pd-103 is necessary, the presence of the Pd reduces loss of Pd-103 occurring during said purification. Lastly, the Pd addition can be used to provide a final product having a desired WO 96115830 s~ ~ ~ ~ (~ ~ PCT/US94/I3486 o specific activity and consequently a predetermined self absorption in the electroplated layer containing the Pd-103.
The amount of palladium added, therefore, will vary depending principally upon the amount of Pd-103 available. Normally, no more than about 0.000075 grams of palladium per pellet are necessary to provide an electroplate layer from which the isotope does not escape. Generally, the amount of palladium metal added falls in the range of 0.00005 to 0.0005 grams per pellet.
zf trace amounts of non-Pd isotopes are present in the solution containing soluble rhodium salts, these are removed at this stage of the process by the following purification procedures:
The solution containing soluble rhodium salts and Pd-103 is then passed through an anion resin exchange column wherein palladium in the form of PdC142- attaches to the column and Rh3+ passes through. Other trace isotopes comprised of elements such as Ru, Co, Zn and the like can then be eluted off the column using hydrochloric acid of different acid strengths for various groups of such elements.
Finally, the mixture of Pd-103 and Pd is eluted off the column with NH40H as palladium amine complex and the palladium amine complex is electroplated onto a suitable electroconductive support.
The electroconductive support onto which the Pd-103 containing complex of the invention is electroplated is preferably in the form of a pellet and can be constructed of any non-toxic, electroconductive material composed of low atomic number so as to minimize internal absorption of the X-ray radiation. The pellet can be of any desired shape, but is pre7Eerably cylindrical. Examples of suitable supports are thosE~ made of carbon, normally in the form of graphite and alum_Lnum.
Of these supports, t=he preferred support is graphite in the form of cylindrical pellets.
The amount o:E Pd-103 in pellet 14 depends upon the radiation dosage oequired for each seed. For a seed having the configuration shown .Ln Fig. 1, pellets having a diameter of 0.023 inch wil:L have a layer of the Pd-103/Pd admixture that preferably contains a specific activity of at least 2.5 Ci/g. The toi=al radiation level emitted by both pellets is more accuratel~~ expressed as an apparent value in mCi which takes into account the self-absorption within the layer of the Pd-103/Pd admixture. By adjusting the specific activity of the Pd-103/Pd admixture and the amount of this admixture plated onto thE~ pellets, the apparent activity level of the seed can be adjusted to between about 0.5 to 300 mCi/seed.
The opaque marker 18 is generally comprised of a high atomic number element which, as a result of its high atomic number, is X-ray opaque. Suitable examples of such elements include lead and :rhodium.
The shell 22 encapsulates the pellets 14 and the opaque marker 18 in such a way that the admixture of radioactive Pd-103/Pd cannot i.~nder normal circumstances come into contact with body tissue or fluids due to this encapsulating shell, thereby foaming an additional barrier to escape and distribution of the radioactive isotope throughout the body.
Accordingly, the outer shell 22 is formed of a material that is biocompatible ~3nd preferably the encapsulating shell is titanium. The wall thickness of the titanium shell is about .001 to .005 inch preferably .002 inch.
Most advantageously, the shell will take-the form of a tube with the ends thereof closed in a manner that precludes direct contact between body tissue and fluids and the internal components of the seed 10. This closure of the ends can be effected, fo:r instance, by swaging shut the open ends and welding. Alternatively, the ends may be closed by capping them in a suitable manner, a preferred example of which is shown in Fig. 1 and Fig. 2. Referring to these figures, it is seen that the outer shell 22 is constructed from a three piece assembly, including the tube 24 and the pair of end caps 26 that are welded to the tube 24 after the other components, i.e., the X-ray-emitting pellets 14 and the X-ray-opaque marker 18 are inserted into the tube. The important advantage of this construction relative to the construction of t:he shells 22 of seeds 10, some presently in commercial production, is that it permits the formation of thinner ends, i.e., about the same thickness as the sidewalls, and thereby provides for a better angular distribution of t:he emitted X-rays. Even though the shell material is selected to be as transparent to X-rays as is consistent with other requirements of the shell material, the shell 22 will absorb some of the low-energy X-rays emitted by the palladium-103. By using end caps 26 having the same thickness as the tube 24, the end of the shell 22 is as thick as the sidewalls of the shell 22, promoting the generally isotropic angular distribution of X-rays from the seed. In the see~3 10 illustrated in Fig. 1, the end caps are cup-shaped, including a circular end wall 27 and an outwardly WO 96/15830 ~ ~ ~ ~ ~ ~ ~ PCT/US94/13486 extending cylindrical sidewall 29. The diameter of the end caps 25 is proportioned to fit closely within the ends of the tube of the seed. After the seed 1 is assembled, the end caps 26 are welded, e.g., with a laser, to the tube 24, thereby permanently sealing the pellets 14 and the marker 18 within the shell. Although this construction produces double-walled sections extending outwardly of the circular end walls 27 of the end caps; a double-walled thickness is less than the thickness of end beads in some currently produced seeds, and the double-walled segment results in additional shielding only along a narrow angular region.
Fig. 2 illustrates an alternative embodiment of a seed 10', in which end caps 26' having side walls 29' are proportioned to overfit the walls of tube 24 and welded thereto. Otherwise, the pellets 14, markers 18 and tube 24 are as described in the Fig.
1 embodiment.
The following example is included to further illustrate the invention, but is to be considered as exemplary only and as not limiting of the invention in any way.
ExAMPLE
Approximately 2 grams of rhodium metal are deposited on a copper substrate to provide a cyclotron target. The target thus prepared is placed in a cyclotron and bombarded with protons having an energy of 14 million electron volts for a period of 160 hours to provide Rh containing carrier-free Pd-103. The Pd-103 containing Rh deposit is removed from the copper substrate and the Pd-103/Pd mixture of the invention recovered using the following procedure.
remove Rh deposit from copper substrate WO 96!15830 ~ ~ ~ ~ ~ ~ PCTIUS94/d3486 Perforate the Rh deposit by mechanically etching with a small electric engraving tool.
Briefly dip the target into a vessel containing enough 6N HN03 to cover the target.
Withdraw the target and rinse with DI water to remove the FiN03 . Dry the target .
Cover the copper surfaces of the target with a chemically inert material so that only the Rh surface is exposed.
~ With only the Rh surface exposed, return the target to the vessel containing HN03 and etch until all the Rh is removed.
Pass the acid solution through a filter funnel containing ashless filter paper catching the Rh fragments in the filter.
Rinse the filter with small portions of deionized (DI) water to remove any residual Cu ions.
Dissolve Rh foil Place filter paper into a quartz crucible and gently push it to the bottom with a tamping rod. Place the crucible into a crucible furnace and heat at 700°C until only a thin white ash remains from the filter paper. This operation should require approximately 30 min.
Remove crucible from furnace and allow to cool to near ambient.
Carefully transfer 30 grams of NaHS04 into the crucible using a powder funnel.
Slowly place crucible with lid in place into crucible furnace at 700°C. Heat for 90 min.
watching carefully during the first 5 minutes to control boiling if necessary.
Remove crucible from furnace and allow to cool to near ambient.
To the crucible, add 20 ml of hot 1M HC1-and stir until the solizlified mars breaks free. Carefully transfer the solution and solid resi~3ue to a 250 ml beaker containing a magnetic stirring bar.
Rinse the crucible with 10 ml portions of 1M HC1 to dissolve any residual s~~lid and add rinses to the beaker.
Stir with gentle heating (keep well below the boiling point) until all solids are dissolved. Taking care not to transfer the stirring bar, pour the contents of the beaker into a filter apparatus containing ashless filter paper retaining both thf~ solid (Rh remaining to be dissolved) and filtrate (dissolvE~d Rh .and Pd-103). Rinse the beaker with small portions of 1M HC1 and pass these through the filter.
Finally, rinse the filter with small portions of 1M HC1 adding this to thE~ filtrate. If solid remains in the filter, return thE~ filt~en to the quartz crucible and repeat all intervening si~eps u:nt:il all Rh fragments are dissolved.
Assay the fi_Ltrate i=or Pd-103 activity and add a volume of PdCl2 solution to the filtrate such that at least 5 mg of Pd is added; the Exact ~amount added depending on the specific activity of Pd-103 desired.
Set up a gra~Tity filter funnel with No. 2 Whatman paper. Add one m:L O.1M AgN03 to the filtrate, slowly mix, and pour through t=he fi.lt:er. Rinse both beaker and filter with DI water.
Prepare an anion e:KC:hange column containing approximately 30 rnl of :resin in the chloride form and a glass wool retain:Lng pl,uc~ on top of the resin bed.
Slowly pour the Rh solution into a reservoir on top of the column. Wash. the transfer beaker 3 times with small portions of O.1M HC1 and. add to the reservoir. Open the stopcock and allow the solution to flow through the column with an elution rate oi: approximately 6 drops per second until the liquid level reaches the top of the glass wool plug above the resin bE:d..
Pass the following solutions through the column at a flow rate of approximately 6 drops per sec.
- 0.03M HC1 - 4m HC1 - DI water. Save this fraction for possible Pd recovery.
- Concentrated NH40H. Elute Pd into a clean 400 ml beaker at a flow hate of 6 drops per second.
- DI water. Combine this wash with the NHqOH.
Make the NH90H/water rinse solution to volume and assay for Pd-103 and trace isotope activity. The specific activity can be calculated from the activity of Pd-103 and mass of Pd added.
High purity graphite rods having a diameter of about 0.023 inch are cut to a~ length of approximately 0.035 inch to form pellets. The graphite pellets are electroplated with the above solution of palladium amine complex to which has been added ammonium chloride and nicotinamide as a plating additive. The electroplating procedures employ ordinary direct electroplating technology. The resulting layer of Pd-103/Pd on each graphite pellet 13 can provide and apparent seed activity of between 0.5 mCi/seed and 300 mCi/seed.
ASTM B265-78, grade 2 titanium is used to form tubular sections, 0.177 i:n. in length, 0.032 in. in outside diameter and 0.028 in. in inside diameter (0.002 in. wall thickness).
The same titanium is used to form end caps, 0.027 in. long, OD 0.028 in., ID 0.024 in., wall thickness (including end walls) of 0.002 i:n.
The seed is constructed by inserting two pellets 14 in the tube 24 segment, flanking a marker 18 formed of a lead rod segment, inserting the caps in the ends of the tube and laser-welding the end caps to the tube.
The advantages offered hereto by commercially available Pd-103 seeds over other .isotopes interstitially implanted such as iridium-192, gold-198 or radon-222 and iodine-125 is well documented. Unlike these isotopes, Pd-103 seeds do not emit high energy gamma rays and the energy of its X-ray radiation is lower. Consequently, the action of Pd-103 radiation is more localized within a tumor, does little damage to surroun~~ing tiasue and is highly attenuated within the body. A Pd-103 seed prepared according to the present invention offers all of 'these same advantages and, in addition, isotopi~cally pure seeds using smaller amounts of Pd-103 since the specific activity of the Pd-103/Pd admixture used in their production can be adjusted to minimize'the self-absorbing properties of the electroplated layer. An additi~cnal advantage over previously available Pd-103 seeds is t:he possibility of, by taking advantage of the adjustable specific activity of Pd-103 afforded by this invention to produce seeds of much higher (at least a factor of times 3) apparent activity than previously possible.
The small size of the Pd-103 seed of the present invention allows 'them to be permanently implanted with a WO 96/15830 ~ PCT/US94/I3486 ~ minimum of tissue trauma. They may be injected through a #17 gauge needle or may be implanted using established applicators such as Scott, Mick or ~Ienschke applicators.
Once implanted, they can be left there indefinitely, thereby reducing the risk of infection, radiation exposure and surgical complications that often accompany removable implants.
While the invention has been described in terms of certain preferred embodiments, modification obvious to one of ordinary skill in the art may be made without departing from the scope of the invention.
Lastly, reactor produced Pd-103 from Pd-102 enriched Pd not only is costly because of the difficulty in enriching Pd metal in Pd-102, but poses environmental problems. Producing Pd-103 with a reactor requires the fission of uranium to produce the required neutrons. An adequate means to dispose of the resulting transuranic waste is still a subject of debate. The larger amounts of contaminant~isotopes produced in a reactor target also present a disposal problem. Since electric power is the only requirement to make a cyclotron function and contaminant isotope production is much less, cyclotron produced Pd-103 has far less of an environmental impact.
It is apparent therefore that if it were possible to produce a seed of Pd-103 of sufficient purity and desired therapeutic activity via the cyclotron route that was also safe, that the advantages it would present over the presently commercially available Pd-103 seeds would be of immeasurable value.
It is an object of the invention,.therefore, to provide a seed of Pd-103 of high isotopic purity and desired therapeutic activity that is also safe for use as an interstitial implant. By the term wo 96n5s3o ~ ~ ~ ~ ~ ~ ~ PCTIUS94/13486 -"safe" as used herein and in appended claims is meant a seed characterized by being non-toxic and having radioisotopically pure Pd-103 bonded to the support carrying same in a manner that preclude .5 release therefrom, thereby substantially reducing the chances of the radioactive isotope leaking into the circulatory system of the patient.
Another object of the invention is to provide an interstitial seed composed of carrier free Pd-103 having added to it small amounts of palladium metal, which seed has an isotopic purity such that the ratio of the radiation absorbed dose to the patient from isotopes other than Pd-103 to that from Pd-103 is less than 0.01 and a specific activity of at least 2.5 Ci/gm.
A further object of the present invention is to provide a process for the production of a safe, Pd-103-containing seed substantially reduced in the self-shielding properties that characterize commercially-available Pd-103 seeds and which therefore enables use of smaller amounts of Pd-103 to achieve the desired X-ray intensity (therapeutic or apparent activity).
Yet another object of the invention is to provide a process for the production of Pd-103 seeds which does not present the purification difficulties encountered in present commercially available Pd-103 production processes.
A further object of the invention is to provide a process for the reproducible production of safe Pd-103 containing seeds of predetermined isotopic purity, self-shielding and therapeutic or apparent activity.
Lastly, the invention provides a process for Pd-103 seed production that is cheaper, does not WO 96/15830 ~ ~ ~ ~ ~ ~ PCT/LTS94/13486 - g -require a difficultly replaced resource (enriched Pd-102) and that poses a reduced threat to the environment.
SUMMARY OF THE INVENTION
These and other objects of the invention are obtained by a process which comprises preparing a seed that is safe for implantation into a tumor within a living body to emit x-ray radiation, said seed having a predetermined radiation level measured as apparent mCi comprising irradiating an Rh metal. target in a charged particle accelerator under conditions that produce carrier-free Pd-103 within said Rh metal, recovering carrier-free Pd-103 from the rhodium metal, adding palladium metal to said carrier-free Pd-103 in a small amount sufficient to promote electroplating of said mixture and to obtain the desired level of self shielding, removing non-palladium isotopes from said admixture, if necessary, electroplating a layer of said Pd-103/palladium admixture having a known specific activity and self absorption onto at least one pellet of an electroconductive material substantially non-absorbing of X-rays, the amount of Pd-103 in said layer being sufficient to provide a radiation level measured as apparent mCi of greater than 0.5, and encapsulating said at least one pellet within a shell of a biocompatible material that is penetrable by X-rays in the 20-23 kev range.
In another aspect of the invention there is obtained a safe seed for implantation into a tumor within a living body to emit x-ray radiation said seed having a predetermined radiation level measured as apparent mCi comprising irradiating a rhodium metal target in a charged particle WO 96!15830 ~ ~ ~ PCT/US94/13486 ~_ accelerator under conditions that produce carrier-free Pd-103 in said rhodium metal, recovering v carrier-free Pd-103 from rhodium metal, adding . palladium metal to said carrier-free Pd-103 in a small amount sufficient to promote electroplating of said mixture and to obtain the desired level of self shielding, removing, if necessary, non-palladium isotopes from said admixture electroplating a layer of said Pd-103/palladium admixture having a known specific activity and self absorption onto at least one pellet of an electroconductive material substantially non-absorbing of X-rays, the amount of Pd-103 in said .
layer being sufficient to provide a radiation level measured as apparent mCi of greater than 0.5, and encapsulating said at least one pellet within a shell of a bicompatible material that is penetrable by X-rays in the 20-23 kev range.
In yet another aspect of the invention, there is provided a seed for safe implantation into tumors which consists of a layer of carrier free Pd-103 having added thereto Pd in an amount that provides a seed having an isotopic purity such~that the ratio of the radiation absorbed dose to the patient from isotopes other than Pd-103 to that from Pd-103 is less than 0.01 and a specific activity of at least 2.5 Ci/gm electroplated onto an electroconductive support, the amount of said Pd being sufficient to promote said electroplating, said at least one electroplated pellet containing Pd-103 in an amount sufficient to provide a radiation level measured as apparent mCi of greater than 0.5, and a shell of a bicompatible material encapsulating said at least one electroplated WO 96/15830 °~~ ~ ~ ~ ~ 4 ~ PCT/LTS94/13486 pellet, said biocompatible material being penetrable by X-rays in the 20-23 kev range.
By the term isotopic purity as used herein and in the appended claims is meant the proportion of the total radiation, absorbed dose due to the specified nuclide, that is, that the dose from other isotopes is less than 1.0% of the Pd-103 dose.
By the term specific activity as used herein and in the appended .claims is meant the total activity of the Pd-103 per gram of the admixture with palladium metal.
By the term "therapeutic or apparent activity" as used herein and the appended claims is meant the Pd-103 activity as determined from measuring the X-ray intensity outside the seed. This is also the therapeutic activity, i.e. the activity that actually kills the cancer and therefore the activity the doctor must use when developing a plan for treating the patient.
$RIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a cut-away view of an implantable X-ray emitting capsule or seed, embodying various features of the present invention; and Fig. 2 is a cut-away view of an alternative embodiment of an implantable seed.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
With reference to the drawings, a seed or capsule 10, embodying features of the invention is 3o implanted at a selected site within a living body and emits localized X-ray radiation therein. The X-rays are emitted from a pair of pellets 14 of generally cylindrical shape of electroconductive material having electroplated thereon the carrier-free Pd-103/Pd admixture of the present invention.
PCTlI7S94113486 wo 96nsg3o Positioned between the two pellets is a rod-shaped marker 18 formed of X-ray-opaque material that provides a means of visualizing the seed 10 with external X-ray equipment after the seed has been implanted in the body.
In accordance with the present invention, a target for use in the charged particle accelerator is prepared by depositing rhodium metal onto a suitable substrate such as a copper or a silver substrate. The rhodium target thus prepared is then placed in a charged particle accelerator such as a cyclotron and bombarded with protons or deuterons. The energy of the impacting particle is chosen so that for all practical purposes the only Pd atoms created on the rhodium target are Pd-103, that is, the Pd-103 is carrier-free. The rhodium metal containing the carrier-free Pd-103 is then placed in a hot cell wherein the rhodium metal is removed from the substrate by, for example, etching away with HN03. This removal is preferably accomplished by mechanically disrupting the continuity of the rhodium layer on the substrate as by perforating the surface with a sharply pointed impact tool. The exposed (i.e. non-deposit-containing) substrate surface is covered to protect it and the perforated target immersed in a HN03 bath. A solution containing rhodium flakes results, which is filtered to recover the solid rhodium flakes containing Pd-103. The recovered rhodium flakes are rinsed on the filter and the flakes together with the filter placed in a crucible and heated to decompose the filter leaving the rhodium metal flakes containing the Pd-103.
The rhodium metal flakes thus obtained are then partially dissolved in molten NaHS04 and the resulting NaHS04/rhodium flake mixture is dissolved in dilute HC1 which provides soluble rhodium salts dissolved in dilute HC1. This procedure is . normally repeated several times so as to dissolve any remaining rhodium metal containing carrier-free palladium-103.
Palladium is then added lusuallv in t-hA
soluble salt such as PdCl2) to the solution containing rhodium salts. Although palladium has a high atomic number and would normally be considered an undesirable additive to a low energy X-ray emitting seed, its addition in accordance with the present invention, has been found to be essential and advantageous in several respects. Foremost, the added palladium promotes the subsequent electroplating and ensures strong adhesive of the Pd-103/Pd mixture to the support therefor, thereby forming a physiologically inert layer which will not allow the radioactive Pd-103 to be mobilized into the circulation of a human should the titanium outer shell be breached and body fluids allowed to come into contact with the Pd-103 containing layer.
Secondly, the addition of palladium metal represents the ability to adjust the specific activity of the Pd-103/palladium mixture electroplated onto the support with the objective of adjusting its self absorption to a known value thus facilitating the manufacture of a seed with an accurately predetermined therapeutic or apparent activity. Thirdly, if further purification of the carrier-free Pd-103 is necessary, the presence of the Pd reduces loss of Pd-103 occurring during said purification. Lastly, the Pd addition can be used to provide a final product having a desired WO 96115830 s~ ~ ~ ~ (~ ~ PCT/US94/I3486 o specific activity and consequently a predetermined self absorption in the electroplated layer containing the Pd-103.
The amount of palladium added, therefore, will vary depending principally upon the amount of Pd-103 available. Normally, no more than about 0.000075 grams of palladium per pellet are necessary to provide an electroplate layer from which the isotope does not escape. Generally, the amount of palladium metal added falls in the range of 0.00005 to 0.0005 grams per pellet.
zf trace amounts of non-Pd isotopes are present in the solution containing soluble rhodium salts, these are removed at this stage of the process by the following purification procedures:
The solution containing soluble rhodium salts and Pd-103 is then passed through an anion resin exchange column wherein palladium in the form of PdC142- attaches to the column and Rh3+ passes through. Other trace isotopes comprised of elements such as Ru, Co, Zn and the like can then be eluted off the column using hydrochloric acid of different acid strengths for various groups of such elements.
Finally, the mixture of Pd-103 and Pd is eluted off the column with NH40H as palladium amine complex and the palladium amine complex is electroplated onto a suitable electroconductive support.
The electroconductive support onto which the Pd-103 containing complex of the invention is electroplated is preferably in the form of a pellet and can be constructed of any non-toxic, electroconductive material composed of low atomic number so as to minimize internal absorption of the X-ray radiation. The pellet can be of any desired shape, but is pre7Eerably cylindrical. Examples of suitable supports are thosE~ made of carbon, normally in the form of graphite and alum_Lnum.
Of these supports, t=he preferred support is graphite in the form of cylindrical pellets.
The amount o:E Pd-103 in pellet 14 depends upon the radiation dosage oequired for each seed. For a seed having the configuration shown .Ln Fig. 1, pellets having a diameter of 0.023 inch wil:L have a layer of the Pd-103/Pd admixture that preferably contains a specific activity of at least 2.5 Ci/g. The toi=al radiation level emitted by both pellets is more accuratel~~ expressed as an apparent value in mCi which takes into account the self-absorption within the layer of the Pd-103/Pd admixture. By adjusting the specific activity of the Pd-103/Pd admixture and the amount of this admixture plated onto thE~ pellets, the apparent activity level of the seed can be adjusted to between about 0.5 to 300 mCi/seed.
The opaque marker 18 is generally comprised of a high atomic number element which, as a result of its high atomic number, is X-ray opaque. Suitable examples of such elements include lead and :rhodium.
The shell 22 encapsulates the pellets 14 and the opaque marker 18 in such a way that the admixture of radioactive Pd-103/Pd cannot i.~nder normal circumstances come into contact with body tissue or fluids due to this encapsulating shell, thereby foaming an additional barrier to escape and distribution of the radioactive isotope throughout the body.
Accordingly, the outer shell 22 is formed of a material that is biocompatible ~3nd preferably the encapsulating shell is titanium. The wall thickness of the titanium shell is about .001 to .005 inch preferably .002 inch.
Most advantageously, the shell will take-the form of a tube with the ends thereof closed in a manner that precludes direct contact between body tissue and fluids and the internal components of the seed 10. This closure of the ends can be effected, fo:r instance, by swaging shut the open ends and welding. Alternatively, the ends may be closed by capping them in a suitable manner, a preferred example of which is shown in Fig. 1 and Fig. 2. Referring to these figures, it is seen that the outer shell 22 is constructed from a three piece assembly, including the tube 24 and the pair of end caps 26 that are welded to the tube 24 after the other components, i.e., the X-ray-emitting pellets 14 and the X-ray-opaque marker 18 are inserted into the tube. The important advantage of this construction relative to the construction of t:he shells 22 of seeds 10, some presently in commercial production, is that it permits the formation of thinner ends, i.e., about the same thickness as the sidewalls, and thereby provides for a better angular distribution of t:he emitted X-rays. Even though the shell material is selected to be as transparent to X-rays as is consistent with other requirements of the shell material, the shell 22 will absorb some of the low-energy X-rays emitted by the palladium-103. By using end caps 26 having the same thickness as the tube 24, the end of the shell 22 is as thick as the sidewalls of the shell 22, promoting the generally isotropic angular distribution of X-rays from the seed. In the see~3 10 illustrated in Fig. 1, the end caps are cup-shaped, including a circular end wall 27 and an outwardly WO 96/15830 ~ ~ ~ ~ ~ ~ ~ PCT/US94/13486 extending cylindrical sidewall 29. The diameter of the end caps 25 is proportioned to fit closely within the ends of the tube of the seed. After the seed 1 is assembled, the end caps 26 are welded, e.g., with a laser, to the tube 24, thereby permanently sealing the pellets 14 and the marker 18 within the shell. Although this construction produces double-walled sections extending outwardly of the circular end walls 27 of the end caps; a double-walled thickness is less than the thickness of end beads in some currently produced seeds, and the double-walled segment results in additional shielding only along a narrow angular region.
Fig. 2 illustrates an alternative embodiment of a seed 10', in which end caps 26' having side walls 29' are proportioned to overfit the walls of tube 24 and welded thereto. Otherwise, the pellets 14, markers 18 and tube 24 are as described in the Fig.
1 embodiment.
The following example is included to further illustrate the invention, but is to be considered as exemplary only and as not limiting of the invention in any way.
ExAMPLE
Approximately 2 grams of rhodium metal are deposited on a copper substrate to provide a cyclotron target. The target thus prepared is placed in a cyclotron and bombarded with protons having an energy of 14 million electron volts for a period of 160 hours to provide Rh containing carrier-free Pd-103. The Pd-103 containing Rh deposit is removed from the copper substrate and the Pd-103/Pd mixture of the invention recovered using the following procedure.
remove Rh deposit from copper substrate WO 96!15830 ~ ~ ~ ~ ~ ~ PCTIUS94/d3486 Perforate the Rh deposit by mechanically etching with a small electric engraving tool.
Briefly dip the target into a vessel containing enough 6N HN03 to cover the target.
Withdraw the target and rinse with DI water to remove the FiN03 . Dry the target .
Cover the copper surfaces of the target with a chemically inert material so that only the Rh surface is exposed.
~ With only the Rh surface exposed, return the target to the vessel containing HN03 and etch until all the Rh is removed.
Pass the acid solution through a filter funnel containing ashless filter paper catching the Rh fragments in the filter.
Rinse the filter with small portions of deionized (DI) water to remove any residual Cu ions.
Dissolve Rh foil Place filter paper into a quartz crucible and gently push it to the bottom with a tamping rod. Place the crucible into a crucible furnace and heat at 700°C until only a thin white ash remains from the filter paper. This operation should require approximately 30 min.
Remove crucible from furnace and allow to cool to near ambient.
Carefully transfer 30 grams of NaHS04 into the crucible using a powder funnel.
Slowly place crucible with lid in place into crucible furnace at 700°C. Heat for 90 min.
watching carefully during the first 5 minutes to control boiling if necessary.
Remove crucible from furnace and allow to cool to near ambient.
To the crucible, add 20 ml of hot 1M HC1-and stir until the solizlified mars breaks free. Carefully transfer the solution and solid resi~3ue to a 250 ml beaker containing a magnetic stirring bar.
Rinse the crucible with 10 ml portions of 1M HC1 to dissolve any residual s~~lid and add rinses to the beaker.
Stir with gentle heating (keep well below the boiling point) until all solids are dissolved. Taking care not to transfer the stirring bar, pour the contents of the beaker into a filter apparatus containing ashless filter paper retaining both thf~ solid (Rh remaining to be dissolved) and filtrate (dissolvE~d Rh .and Pd-103). Rinse the beaker with small portions of 1M HC1 and pass these through the filter.
Finally, rinse the filter with small portions of 1M HC1 adding this to thE~ filtrate. If solid remains in the filter, return thE~ filt~en to the quartz crucible and repeat all intervening si~eps u:nt:il all Rh fragments are dissolved.
Assay the fi_Ltrate i=or Pd-103 activity and add a volume of PdCl2 solution to the filtrate such that at least 5 mg of Pd is added; the Exact ~amount added depending on the specific activity of Pd-103 desired.
Set up a gra~Tity filter funnel with No. 2 Whatman paper. Add one m:L O.1M AgN03 to the filtrate, slowly mix, and pour through t=he fi.lt:er. Rinse both beaker and filter with DI water.
Prepare an anion e:KC:hange column containing approximately 30 rnl of :resin in the chloride form and a glass wool retain:Lng pl,uc~ on top of the resin bed.
Slowly pour the Rh solution into a reservoir on top of the column. Wash. the transfer beaker 3 times with small portions of O.1M HC1 and. add to the reservoir. Open the stopcock and allow the solution to flow through the column with an elution rate oi: approximately 6 drops per second until the liquid level reaches the top of the glass wool plug above the resin bE:d..
Pass the following solutions through the column at a flow rate of approximately 6 drops per sec.
- 0.03M HC1 - 4m HC1 - DI water. Save this fraction for possible Pd recovery.
- Concentrated NH40H. Elute Pd into a clean 400 ml beaker at a flow hate of 6 drops per second.
- DI water. Combine this wash with the NHqOH.
Make the NH90H/water rinse solution to volume and assay for Pd-103 and trace isotope activity. The specific activity can be calculated from the activity of Pd-103 and mass of Pd added.
High purity graphite rods having a diameter of about 0.023 inch are cut to a~ length of approximately 0.035 inch to form pellets. The graphite pellets are electroplated with the above solution of palladium amine complex to which has been added ammonium chloride and nicotinamide as a plating additive. The electroplating procedures employ ordinary direct electroplating technology. The resulting layer of Pd-103/Pd on each graphite pellet 13 can provide and apparent seed activity of between 0.5 mCi/seed and 300 mCi/seed.
ASTM B265-78, grade 2 titanium is used to form tubular sections, 0.177 i:n. in length, 0.032 in. in outside diameter and 0.028 in. in inside diameter (0.002 in. wall thickness).
The same titanium is used to form end caps, 0.027 in. long, OD 0.028 in., ID 0.024 in., wall thickness (including end walls) of 0.002 i:n.
The seed is constructed by inserting two pellets 14 in the tube 24 segment, flanking a marker 18 formed of a lead rod segment, inserting the caps in the ends of the tube and laser-welding the end caps to the tube.
The advantages offered hereto by commercially available Pd-103 seeds over other .isotopes interstitially implanted such as iridium-192, gold-198 or radon-222 and iodine-125 is well documented. Unlike these isotopes, Pd-103 seeds do not emit high energy gamma rays and the energy of its X-ray radiation is lower. Consequently, the action of Pd-103 radiation is more localized within a tumor, does little damage to surroun~~ing tiasue and is highly attenuated within the body. A Pd-103 seed prepared according to the present invention offers all of 'these same advantages and, in addition, isotopi~cally pure seeds using smaller amounts of Pd-103 since the specific activity of the Pd-103/Pd admixture used in their production can be adjusted to minimize'the self-absorbing properties of the electroplated layer. An additi~cnal advantage over previously available Pd-103 seeds is t:he possibility of, by taking advantage of the adjustable specific activity of Pd-103 afforded by this invention to produce seeds of much higher (at least a factor of times 3) apparent activity than previously possible.
The small size of the Pd-103 seed of the present invention allows 'them to be permanently implanted with a WO 96/15830 ~ PCT/US94/I3486 ~ minimum of tissue trauma. They may be injected through a #17 gauge needle or may be implanted using established applicators such as Scott, Mick or ~Ienschke applicators.
Once implanted, they can be left there indefinitely, thereby reducing the risk of infection, radiation exposure and surgical complications that often accompany removable implants.
While the invention has been described in terms of certain preferred embodiments, modification obvious to one of ordinary skill in the art may be made without departing from the scope of the invention.
Claims (10)
1. A seed for implantation into a living body to emit X-ray radiation thereto which includes X-ray emitting material bonded to a support encapsulated by a biocompatible material characterized in that the seed contains, as the X-ray emitting material, carrier-free palladium-103 in an amount sufficient to provide an apparent activity measured from outside the seed of greater that 1.85 x 10 7 Bq/seed and wherein the X-ray emitting material is bonded to the support in a manner that precludes release of the X-ray emitting material from the support when the X-ray emitting material is exposed to the body fluids or tissue of a patient.
2. An implantable seed as claimed in claim 1 further including an amount of palladium metal sufficient to promote electroplating of a composition including palladium metal and carrier-free palladium-103 onto the support.
3. An implantable seed as claimed in any one of claims 1-2 wherein the support is electro conductive.
4. An implantable seed as claimed in any one of claims 1-3 wherein the biocompatible material forms a shell which encapsulates the support with the X-ray emitting material bonded thereto.
5. An implantable seed as claimed in any one of claims 1-4 wherein the X-ray emitting material is present in a layer on the support to promote a generally isotropic distribution of X-rays emitted from the: seed and the biocompatible shell includes titanium.
6. An implantable seed as claimed in any one of claims 1 wherein the seed contains sufficient X-ray emitting material to provide an apparent activity measured from outside the seed of greater than 1.11 x 10 10 Bq/seed.
7. An implantable seed as claimed in any one of claims 1-6 wherein the shell has a generally tubular configuration, the seed includes at least two pellets of X-ray emitting material bonded to a support and an X-ray opaque marker generally centrally located between the at least two pellets with one pellet disposed on either side of the marker to promote a generally isotropic distribution of X-rays emitted from the seed.
8. A method of making a seed having a predetermined activity for implantation within a living body to emit X-ray radiation including the steps of preparing an X-ray emitting composition including palladium-103, electroplating the X-ray emitting composition onto an electro conductive support and encapsulating the X-ray emitting composition with a biocompatible material, characterized in that;
the step of preparing an X-ray emitting composition is carried out by irradiating a rhodium metal target in charged particle accelerator under conditions that produce carrier-free palladium-103 from rhodium metal, and forming an admixture of carrier-free palladium-103 and an amount of a palladium metal salt sufficient to promote electroplating of an admixture of carrier-free palladium-103 and palladium metal onto the electro conductive support and provide a predetermined apparent activity measured from outside the seed of greater than 1.85 x 10 7 Bq/seed.
the step of preparing an X-ray emitting composition is carried out by irradiating a rhodium metal target in charged particle accelerator under conditions that produce carrier-free palladium-103 from rhodium metal, and forming an admixture of carrier-free palladium-103 and an amount of a palladium metal salt sufficient to promote electroplating of an admixture of carrier-free palladium-103 and palladium metal onto the electro conductive support and provide a predetermined apparent activity measured from outside the seed of greater than 1.85 x 10 7 Bq/seed.
9. A method as claimed in claim 8 further including the step of removing substantially all non-palladium isotopes from the admixture of carrier-free palladium-103 and palladium metal salt prior to the electroplating step.
10. A method as claimed in any one of claims 8-9 wherein the step of electroplating forms a layer of X-ray emitting composition on the support to promote a generally isotropic distribution of X-rays emitted from the seed and the admixture of carrier-free palladium-103 and palladium metal in the layer provides an apparent activity measured from outside the seed of greater than 1.11 x 10 10 Bq/seed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/053,422 US5405309A (en) | 1993-04-28 | 1993-04-28 | X-ray emitting interstitial implants |
PCT/US1994/013486 WO1996015830A1 (en) | 1993-04-28 | 1994-11-22 | X-ray emitting interstitial implants |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2199945A1 CA2199945A1 (en) | 1996-05-30 |
CA2199945C true CA2199945C (en) | 2000-02-08 |
Family
ID=37401482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002199945A Expired - Lifetime CA2199945C (en) | 1993-04-28 | 1994-11-22 | X-ray emitting interstitial implants |
Country Status (8)
Country | Link |
---|---|
US (1) | US5405309A (en) |
EP (1) | EP0793519A4 (en) |
JP (1) | JPH10511567A (en) |
AU (1) | AU690616B2 (en) |
CA (1) | CA2199945C (en) |
NZ (1) | NZ277384A (en) |
WO (1) | WO1996015830A1 (en) |
ZA (1) | ZA949681B (en) |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0813894B1 (en) * | 1993-07-01 | 2001-12-05 | Schneider (Europe) GmbH | Medical appliances for the treatment of blood vessels by means of ionizing radiation |
ATE170708T1 (en) | 1994-06-10 | 1998-09-15 | Schneider Europ Gmbh | MEDICINAL DEVICE FOR THE TREATMENT OF A PART OF BODY VESSEL USING IONIZATION RADIATION |
EP0688580B1 (en) | 1994-06-24 | 2000-10-04 | Schneider (Europe) GmbH | Medical appliance for the treatment of a portion of body vessel by ionising radiation |
US5683345A (en) * | 1994-10-27 | 1997-11-04 | Novoste Corporation | Method and apparatus for treating a desired area in the vascular system of a patient |
ATE192346T1 (en) * | 1995-06-22 | 2000-05-15 | Schneider Europ Gmbh | MEDICINAL DEVICE FOR THE TREATMENT OF A PART OF A BODY VESSEL USING IONIZATION RADIATION |
WO1997007122A2 (en) * | 1995-08-09 | 1997-02-27 | Washington University | PRODUCTION OF 64Cu AND OTHER RADIONUCLIDES USING A CHARGED-PARTICLE ACCELERATOR |
US5713828A (en) * | 1995-11-27 | 1998-02-03 | International Brachytherapy S.A | Hollow-tube brachytherapy device |
US6589502B1 (en) | 1995-11-27 | 2003-07-08 | International Brachytherapy S.A. | Radioisotope dispersed in a matrix for brachytherapy |
DE69530302T2 (en) * | 1995-12-05 | 2004-01-29 | Schneider Europ Gmbh Buelach | A filament for irradiating a living body and a method for producing a filament for irradiating a living body |
US6099454A (en) * | 1996-02-29 | 2000-08-08 | Scimed Life Systems, Inc. | Perfusion balloon and radioactive wire delivery system |
US5855546A (en) | 1996-02-29 | 1999-01-05 | Sci-Med Life Systems | Perfusion balloon and radioactive wire delivery system |
US5882290A (en) * | 1996-02-29 | 1999-03-16 | Scimed Life Systems, Inc. | Intravascular radiation delivery system |
US6234951B1 (en) | 1996-02-29 | 2001-05-22 | Scimed Life Systems, Inc. | Intravascular radiation delivery system |
WO1998019740A1 (en) * | 1996-11-05 | 1998-05-14 | Duke University | Radionuclide production using intense electron beams |
US6676590B1 (en) | 1997-03-06 | 2004-01-13 | Scimed Life Systems, Inc. | Catheter system having tubular radiation source |
US6059713A (en) * | 1997-03-06 | 2000-05-09 | Scimed Life Systems, Inc. | Catheter system having tubular radiation source with movable guide wire |
US6110097A (en) * | 1997-03-06 | 2000-08-29 | Scimed Life Systems, Inc. | Perfusion balloon catheter with radioactive source |
US6059812A (en) | 1997-03-21 | 2000-05-09 | Schneider (Usa) Inc. | Self-expanding medical device for centering radioactive treatment sources in body vessels |
US5976067A (en) * | 1997-05-28 | 1999-11-02 | Ablation Technologies, Inc. | Combination radioactive and temperature self-regulating thermal seed implant for treating tumors |
US6019718A (en) | 1997-05-30 | 2000-02-01 | Scimed Life Systems, Inc. | Apparatus for intravascular radioactive treatment |
DE59708672D1 (en) | 1997-09-26 | 2002-12-12 | Schneider Europ Gmbh Buelach | Balloon catheter inflated with carbon dioxide for radiotherapy |
US6471630B1 (en) | 1998-03-24 | 2002-10-29 | Radiomed Corporation | Transmutable radiotherapy device |
US6419621B1 (en) | 1997-10-24 | 2002-07-16 | Radiomed Corporation | Coiled brachytherapy device |
US6264596B1 (en) | 1997-11-03 | 2001-07-24 | Meadox Medicals, Inc. | In-situ radioactive medical device |
SK6752000A3 (en) | 1997-11-14 | 2000-10-09 | Du Pont Pharm Co | Process for the selective oxidation of organic compounds |
WO1999033063A1 (en) * | 1997-12-19 | 1999-07-01 | Robert Robertson | Method and system for making radioactive sources for interstitial brachytherapy and sources made thereby |
US6394945B1 (en) | 1997-12-22 | 2002-05-28 | Mds (Canada), Inc. | Radioactively coated devices |
US6103295A (en) * | 1997-12-22 | 2000-08-15 | Mds Nordion Inc. | Method of affixing radioisotopes onto the surface of a device |
US6060036A (en) * | 1998-02-09 | 2000-05-09 | Implant Sciences Corporation | Radioactive seed implants |
EP1054707B1 (en) | 1998-02-12 | 2005-04-27 | Robert Robertson | Encapsulated low-energy brachytherapy sources |
US6293899B1 (en) * | 1998-03-24 | 2001-09-25 | Radiomed Corporation | Transmutable radiotherapy device |
US5997463A (en) * | 1998-03-26 | 1999-12-07 | North American Scientific | Laser welded brachytherapy source and method of making the same |
CA2326977A1 (en) | 1998-04-03 | 1999-10-14 | Dupont Pharmaceuticals Company | Inorganic material for radioactive drug delivery |
US6143431A (en) * | 1998-05-04 | 2000-11-07 | Webster; Brian A. | Production of Palladium-103 |
US6086942A (en) | 1998-05-27 | 2000-07-11 | International Brachytherapy S.A. | Fluid-jet deposition of radioactive material for brachytherapy devices |
US6264598B1 (en) * | 1998-08-06 | 2001-07-24 | Implant Sciences Corporation | Palladium coated implant |
US6007475A (en) * | 1998-08-12 | 1999-12-28 | Cns Technology, Inc. | Radioactive therapeutic seeds |
US6080099A (en) | 1998-08-12 | 2000-06-27 | Syntheon, Llc | Radioactive therapeutic seeds |
US7011619B1 (en) * | 1998-08-13 | 2006-03-14 | Ge Healthcare Limited | Apparatus and methods for radiotherapy |
US6413203B1 (en) | 1998-09-16 | 2002-07-02 | Scimed Life Systems, Inc. | Method and apparatus for positioning radioactive fluids within a body lumen |
US6148236A (en) * | 1998-11-04 | 2000-11-14 | Urologix, Inc. | Cancer treatment system employing supplemented thermal therapy |
US6395405B1 (en) | 1998-11-09 | 2002-05-28 | Robert E. Buxbaum | Hydrogen permeable membrane and hydride battery composition |
WO2000029501A1 (en) | 1998-11-18 | 2000-05-25 | Emory University | Radioactive coating solutions, methods, and substrates |
DK1131185T3 (en) * | 1998-11-20 | 2005-10-03 | Amersham Health As | Welding method and apparatus |
US6471631B1 (en) | 1998-11-27 | 2002-10-29 | Syntheon, Llc | Implantable radiation therapy device having controllable radiation emission |
US6066083A (en) * | 1998-11-27 | 2000-05-23 | Syntheon Llc | Implantable brachytherapy device having at least partial deactivation capability |
DE19859101C1 (en) * | 1998-12-12 | 2000-05-31 | Eurotope Entwicklungsgesellsch | Miniature palladium-103 radioactivity source useful for interstitial tumor therapy comprises a ceramic tube impregnated with palladium 103, an X-ray marker in the lumen of the tube, and a sheath of biocompatible material |
DE19859100C1 (en) * | 1998-12-12 | 2000-05-31 | Eurotope Entwicklungsgesellsch | Miniature palladium-103 radioactivity source comprises a ceramic tube containing palladium 103, an X-ray marker in the lumen of the tube, and a sheath of biocompatible material, useful for interstitial tumor therapy |
US6482143B1 (en) | 1999-02-28 | 2002-11-19 | Syntheon, Llc | Raidoactive therapeutic seed having selective marker configuration |
US6200258B1 (en) | 1999-08-10 | 2001-03-13 | Syntheon, Llc | Radioactive therapeutic seed having selective marker configuration |
US6730349B2 (en) * | 1999-04-19 | 2004-05-04 | Scimed Life Systems, Inc. | Mechanical and acoustical suspension coating of medical implants |
US6368658B1 (en) * | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
US6547816B1 (en) * | 1999-07-12 | 2003-04-15 | Civatech Corporation | Formable integral source material for medical devices |
US6130926A (en) * | 1999-07-27 | 2000-10-10 | Amini; Behrouz | Method and machine for enhancing generation of nuclear particles and radionuclides |
US6264599B1 (en) | 1999-08-10 | 2001-07-24 | Syntheon, Llc | Radioactive therapeutic seeds having fixation structure |
US6352501B1 (en) | 1999-09-23 | 2002-03-05 | Scimed Life Systems, Inc. | Adjustable radiation source |
US6203485B1 (en) | 1999-10-07 | 2001-03-20 | Scimed Life Systems, Inc. | Low attenuation guide wire for intravascular radiation delivery |
US6398709B1 (en) | 1999-10-19 | 2002-06-04 | Scimed Life Systems, Inc. | Elongated member for intravascular delivery of radiation |
US6436026B1 (en) | 1999-10-22 | 2002-08-20 | Radiomed Corporation | Flexible, continuous, axially elastic interstitial brachytherapy source |
US6416457B1 (en) | 2000-03-09 | 2002-07-09 | Scimed Life Systems, Inc. | System and method for intravascular ionizing tandem radiation therapy |
US6302865B1 (en) | 2000-03-13 | 2001-10-16 | Scimed Life Systems, Inc. | Intravascular guidewire with perfusion lumen |
US6403916B1 (en) | 2000-05-12 | 2002-06-11 | Isostar International, Inc. | System and automated method for producing welded end closures in thin-walled metal tubes |
US6994688B2 (en) * | 2000-05-18 | 2006-02-07 | Theragenics Corporation | Catheter attachment and catheter for brachytherapy |
US6749553B2 (en) * | 2000-05-18 | 2004-06-15 | Theragenics Corporation | Radiation delivery devices and methods for their manufacture |
WO2002007784A2 (en) * | 2000-07-17 | 2002-01-31 | Medi-Physics, Inc. | CARRIER-FREE 103Pd BRACHYTHERAPY SEEDS |
EP1545705A4 (en) | 2000-11-16 | 2010-04-28 | Microspherix Llc | Flexible and/or elastic brachytherapy seed or strand |
US6638205B1 (en) | 2000-11-17 | 2003-10-28 | Mds (Canada) Inc. | Radioactive medical device for radiation therapy |
EP1208874B1 (en) | 2000-11-17 | 2006-11-02 | MDS (Canada) Inc. | Radioactive medical device for radiation therapy |
US6527693B2 (en) * | 2001-01-30 | 2003-03-04 | Implant Sciences Corporation | Methods and implants for providing radiation to a patient |
DE10110196A1 (en) * | 2001-02-14 | 2002-08-22 | Heinz Busch | Seed for brachytherapy in various medical applications |
US20020169354A1 (en) | 2001-05-10 | 2002-11-14 | Munro John J. | Brachytherapy systems and methods |
US6471632B1 (en) | 2001-05-18 | 2002-10-29 | Syntheon, Llc | Radioactive therapeutic seeds |
US6497647B1 (en) | 2001-07-18 | 2002-12-24 | Ati Medical, Inc. | Radiation and thermal energy source |
US6761680B2 (en) * | 2001-11-02 | 2004-07-13 | Richard A. Terwilliger | Delivery system and method for interstitial radiation therapy using seed strands constructed with preformed strand housing |
US7074291B2 (en) | 2001-11-02 | 2006-07-11 | Worldwide Medical Technologies, L.L.C. | Delivery system and method for interstitial radiation therapy using strands constructed with extruded strand housings |
US7060020B2 (en) | 2001-11-02 | 2006-06-13 | Ideamatrix, Inc. | Delivery system and method for interstitial radiation therapy |
IL147199A (en) * | 2001-12-20 | 2007-06-03 | Yuval Golan | Method for packing electrochemically-deposited elements |
US20030165614A1 (en) * | 2002-03-01 | 2003-09-04 | Henrik Hansen | Coating a medical implant using a pan coater |
US6918869B2 (en) | 2002-12-02 | 2005-07-19 | Scimed Life Systems | System for administering a combination of therapies to a body lumen |
US6997862B2 (en) * | 2003-05-13 | 2006-02-14 | Ideamatrix, Inc. | Delivery system and method for interstitial radiation therapy using seed strands with custom end spacing |
US20050245785A1 (en) * | 2003-10-29 | 2005-11-03 | Tarone Theodore T | Biodegradable seed placement device and method |
US7410458B2 (en) * | 2003-11-12 | 2008-08-12 | Isoray Medical, Inc. | Brachytherapy implant seeds |
EA011724B1 (en) * | 2004-06-28 | 2009-04-28 | Айсорей Медикал, Инк. | Method of separating and purifying cesium-131 from barium nitrate |
US7517508B2 (en) * | 2004-07-26 | 2009-04-14 | Isoray Medical, Inc. | Method of separating and purifying Yttrium-90 from Strontium-90 |
CA2576907C (en) * | 2004-07-28 | 2014-04-22 | Isoray Medical, Inc. | Method of separating and purifying cesium-131 from barium carbonate |
US7316644B2 (en) * | 2004-08-18 | 2008-01-08 | Isoray Medical, Inc. | Method for preparing particles of radioactive powder containing Cesium-131 for use in brachytherapy sources |
EP1807844B1 (en) * | 2004-09-28 | 2010-05-19 | Soreq Nuclear Research Center Israel Atomic Energy Commission | Method and system for production of radioisotopes |
US7957507B2 (en) * | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
US8232535B2 (en) | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
US8187159B2 (en) | 2005-07-22 | 2012-05-29 | Biocompatibles, UK | Therapeutic member including a rail used in brachytherapy and other radiation therapy |
EP1907059A4 (en) * | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | Method of and system for predicting dose delivery |
EP2532386A3 (en) * | 2005-07-22 | 2013-02-20 | TomoTherapy, Inc. | System for delivering radiation therapy to a moving region of interest |
US20070041498A1 (en) * | 2005-07-22 | 2007-02-22 | Olivera Gustavo H | System and method of remotely directing radiation therapy treatment |
KR20080039925A (en) * | 2005-07-22 | 2008-05-07 | 토모테라피 인코포레이티드 | Method and system for adapting a radiation therapy treatment plan based on a biological model |
KR20080049716A (en) | 2005-07-22 | 2008-06-04 | 토모테라피 인코포레이티드 | Method and system for evaluating quality assurance criteria in delivery of a treament plan |
ATE507879T1 (en) | 2005-07-22 | 2011-05-15 | Tomotherapy Inc | SYSTEM FOR ADMINISTERING RADIATION THERAPY TO A MOVING TARGET AREA |
US7736293B2 (en) * | 2005-07-22 | 2010-06-15 | Biocompatibles Uk Limited | Implants for use in brachytherapy and other radiation therapy that resist migration and rotation |
KR20080039920A (en) * | 2005-07-22 | 2008-05-07 | 토모테라피 인코포레이티드 | System and method of evaluating dose delivered by a radiation therapy system |
EP1907981A4 (en) | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | Method and system for evaluating delivered dose |
US20070195922A1 (en) * | 2005-07-22 | 2007-08-23 | Mackie Thomas R | System and method of monitoring the operation of a medical device |
JP2009514559A (en) | 2005-07-22 | 2009-04-09 | トモセラピー・インコーポレーテッド | System and method for generating contour structure using dose volume histogram |
KR20080044252A (en) * | 2005-07-22 | 2008-05-20 | 토모테라피 인코포레이티드 | Method and system for processing data relating to a radiation therapy treatment plan |
CA2616299A1 (en) | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | Method of placing constraints on a deformation map and system for implementing same |
US8442287B2 (en) * | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
CA2616293A1 (en) | 2005-07-23 | 2007-02-01 | Tomotherapy Incorporated | Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch |
WO2007100847A2 (en) * | 2006-02-28 | 2007-09-07 | Isoray Medical, Inc. | Method for improving the recovery and purity of cesium-131 from irradiated barium carbonate |
US7988611B2 (en) * | 2006-05-09 | 2011-08-02 | Biocompatibles Uk Limited | After-loader for positioning implants for needle delivery in brachytherapy and other radiation therapy |
US20090216063A1 (en) * | 2008-01-29 | 2009-08-27 | Biocompatibles Uk Limited | Bio-absorbable brachytherapy strands |
US7686756B2 (en) * | 2006-08-29 | 2010-03-30 | Ciratech Oncology | Brachytherapy devices and related methods and computer program products |
US7874976B1 (en) | 2006-09-07 | 2011-01-25 | Biocompatibles Uk Limited | Echogenic strands and spacers therein |
US7878964B1 (en) | 2006-09-07 | 2011-02-01 | Biocompatibles Uk Limited | Echogenic spacers and strands |
US20080269540A1 (en) * | 2007-04-27 | 2008-10-30 | Worldwide Medical Technologies Llc | Seed cartridge adaptor and methods for use therewith |
WO2009055775A2 (en) * | 2007-10-25 | 2009-04-30 | Tomotherapy Incorporated | Method for adapting fractionation of a radiation therapy dose |
KR101409458B1 (en) * | 2007-11-28 | 2014-06-19 | 삼성전자주식회사 | Portable communication terminal having an aromatic function and apparatus for charging communication terminal having the same |
CA2716598A1 (en) * | 2008-03-04 | 2009-09-11 | Tomotherapy Incorporated | Method and system for improved image segmentation |
US20090233993A1 (en) * | 2008-03-06 | 2009-09-17 | Burnham Institute For Medical Research | Compositions and methods for inhibiting gsk3 activity and uses thereof |
US8363784B2 (en) * | 2008-08-28 | 2013-01-29 | Tomotherapy Incorporated | System and method of calculating dose uncertainty |
US8803910B2 (en) * | 2008-08-28 | 2014-08-12 | Tomotherapy Incorporated | System and method of contouring a target area |
EP2403600A4 (en) * | 2009-03-03 | 2012-08-29 | Tomotherapy Inc | System and method of optimizing a heterogeneous radiation dose to be delivered to a patient |
US9061141B2 (en) * | 2009-09-29 | 2015-06-23 | Tomotherapy Incorporated | Patient support device with low attenuation properties |
WO2011053802A2 (en) * | 2009-10-30 | 2011-05-05 | Tomotherapy Incorporated | Non-voxel-based broad-beam (nvbb) algorithm for intensity modulated radiation therapy dose calculation and plan optimization |
US9636523B2 (en) * | 2010-09-13 | 2017-05-02 | Ryan Lee Smith | Brachytherapy dose verification apparatus, system and method |
EP2747839A4 (en) * | 2011-08-25 | 2015-05-27 | Civatech Oncology | Brachytherapy devices and related methods having microencapsulated brachytherapy materials |
US9443633B2 (en) | 2013-02-26 | 2016-09-13 | Accuray Incorporated | Electromagnetically actuated multi-leaf collimator |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3351049A (en) * | 1965-04-12 | 1967-11-07 | Hazleton Nuclear Science Corp | Therapeutic metal seed containing within a radioactive isotope disposed on a carrier and method of manufacture |
US4323055A (en) * | 1980-04-08 | 1982-04-06 | Minnesota Mining And Manufacturing Company | Radioactive iodine seed |
US4702228A (en) * | 1985-01-24 | 1987-10-27 | Theragenics Corporation | X-ray-emitting interstitial implants |
US4891165A (en) * | 1988-07-28 | 1990-01-02 | Best Industries, Inc. | Device and method for encapsulating radioactive materials |
US4994013A (en) * | 1988-07-28 | 1991-02-19 | Best Industries, Inc. | Pellet for a radioactive seed |
-
1993
- 1993-04-28 US US08/053,422 patent/US5405309A/en not_active Expired - Lifetime
-
1994
- 1994-01-01 ZA ZA949681A patent/ZA949681B/en unknown
- 1994-11-22 NZ NZ277384A patent/NZ277384A/en unknown
- 1994-11-22 WO PCT/US1994/013486 patent/WO1996015830A1/en not_active Application Discontinuation
- 1994-11-22 AU AU12588/95A patent/AU690616B2/en not_active Ceased
- 1994-11-22 JP JP8516794A patent/JPH10511567A/en active Pending
- 1994-11-22 CA CA002199945A patent/CA2199945C/en not_active Expired - Lifetime
- 1994-11-22 EP EP95903585A patent/EP0793519A4/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
US5405309A (en) | 1995-04-11 |
WO1996015830A1 (en) | 1996-05-30 |
ZA949681B (en) | 1995-10-25 |
EP0793519A1 (en) | 1997-09-10 |
CA2199945A1 (en) | 1996-05-30 |
AU690616B2 (en) | 1998-04-30 |
EP0793519A4 (en) | 1999-01-07 |
AU1258895A (en) | 1996-06-17 |
NZ277384A (en) | 1998-04-27 |
JPH10511567A (en) | 1998-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2199945C (en) | X-ray emitting interstitial implants | |
AU2001266592B2 (en) | Radiation delivery devices and methods for their manufacture | |
DE60210526T2 (en) | Radioactive capsule | |
AU2001266592A1 (en) | Radiation delivery devices and methods for their manufacture | |
US7531150B2 (en) | Method of separating and purifying cesium-131 from barium carbonate | |
EP1076905B1 (en) | Production of palladium-103 | |
EP1766635B1 (en) | Method of separating and purifying cesium-131 from barium nitrate | |
WO2000008651A2 (en) | Palladium coated implant | |
EP1301216B1 (en) | CARRIER-FREE 103 Pd BRACHYTHERAPY SEEDS | |
WO2000029034A1 (en) | Products and methods | |
Drobnik et al. | Carrier-free 103 Pd brachytherapy seeds | |
Aardaneh | Separation of 103Pd from Ag and Rh targets for production of'103 Pd seeds' for prostate cancer brachytherapy | |
AU2008200015A1 (en) | Carrier-free 103ZPd brachytherapy seeds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20141124 |